Oihana Murillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Oihana Murillo has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Melero
Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, 31008 Pamplona, Spain
8 shared publications Ainhoa Arina
Department of Pathology, University of Chicago, Chicago, Illinois, United States of America
6 shared publications- Carlos Alfaro
Centre for Applied Medical Research, Universidad de Navarra, Av. Pio XII 55, 31008 Pamplona, Spain
6 shared publications Juan Dubrot
Center for Applied Medical Research, University of Navarra, Pamplona, Spain
6 shared publications- Gloria Gonzalez-Aseguinolaza
CIMA University of Navarra, Pamplona, Navarra, Spain
5 shared publications - Jose Luis Perez-Gracia
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
5 shared publications
Latest Publications
- 20 May 2019
- Published by Udako Euskal Unibertsitatea
Bektore biral terapeutiko baten efikazia eta toxizitateaten ebaluazioa Wilson gaixotasundun saguetan
Bektore biral terapeutiko baten efikazia eta toxizitateaten ebaluazioa Wilson gaixotasundun saguetan produkzioaren informazio-fitxa
- 20 May 2019
- Published by Udako Euskal Unibertsitatea
Bektore biral terapeutiko baten efikazia eta toxizitateaten ebaluazioa Wilson gaixotasundun saguetan
Bektore biral terapeutiko baten efikazia eta toxizitateaten ebaluazioa Wilson gaixotasundun saguetan produkzioaren informazio-fitxa
- Open Access
- 1 June 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (3) , e243
Brain copper storage after genetic long-term correction in a mouse model of Wilson disease
- 1 June 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (3) , e243
Open AccessBrain copper storage after genetic long-term correction in a mouse model of Wilson disease
- 1 May 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (5) , 1088-1090
Visualization of the therapeutic efficacy of a gene correction approach in Wilson’s disease by laser-ablation inductively coupled mass spectrometry
- 1 May 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (5) , 1088-1090
Visualization of the therapeutic efficacy of a gene correction approach in Wilson’s disease by laser-ablation inductively coupled mass spectrometry
- 31 January 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (3) , 674-683
CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug
Purpose: Head and neck squamous cell carcinoma (HNSCC) is comprised of heterogeneous populations of cells, and CD271 (NGFR; p75NTR) has been associated with a tumor-initiating cell subpopulation. This study assessed the role of CD271 in modulating metastatic behavior in HNSCC. Experimental Design: CD271 was overexpressed in murine and human oral squamous cell carcinoma cells to assess the impact of CD271 activation on the invasive and metastatic phenotype of these cells, using in vitro and orthotopic in vivo modeling. Treatment with human nerve growth factor (NGF) to activate CD271, as well as shRNA knockdown of the CD271-upregulated Snai2 expression, was used to assess the mechanism of the CD271-induced invasive phenotype. Relevance of CD271 expression in human HNSCC was evaluated in patient-derived xenografts (PDX) and primary human oral cancers, annotated with clinical behavior characteristics and survival data. Results: Forced expression of CD271 resulted in a more invasive and metastatic phenotype. Slug, an epithelial-to-mesenchymal transition (EMT)-related transcription factor, encoded by Snai2, was highly expressed in MOC2-CD271 and HSC3-CD271, compared with respective parental cells. CD271 activation by NGF conferred enhanced invasiveness in CD271-overexpressing cells, which was abrogated by Snai2 knockdown. In PDXs and primary human HNSCC, CD271 expression correlated with higher Snai2 expression, greater nodal metastasis, and shorter disease-free survival. Conclusions: Activation of CD271 results in upregulation of Snai2/Slug, which, in turn, results in a more invasive phenotype and an enhanced capacity for metastasis to regional lymph nodes. These findings point to CD271 as a promising, therapeutic target for oral cancer metastasis. Clin Cancer Res; 24(3); 674–83. ©2017 AACR.
- 31 January 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (3) , 674-683
CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug
Purpose: Head and neck squamous cell carcinoma (HNSCC) is comprised of heterogeneous populations of cells, and CD271 (NGFR; p75NTR) has been associated with a tumor-initiating cell subpopulation. This study assessed the role of CD271 in modulating metastatic behavior in HNSCC. Experimental Design: CD271 was overexpressed in murine and human oral squamous cell carcinoma cells to assess the impact of CD271 activation on the invasive and metastatic phenotype of these cells, using in vitro and orthotopic in vivo modeling. Treatment with human nerve growth factor (NGF) to activate CD271, as well as shRNA knockdown of the CD271-upregulated Snai2 expression, was used to assess the mechanism of the CD271-induced invasive phenotype. Relevance of CD271 expression in human HNSCC was evaluated in patient-derived xenografts (PDX) and primary human oral cancers, annotated with clinical behavior characteristics and survival data. Results: Forced expression of CD271 resulted in a more invasive and metastatic phenotype. Slug, an epithelial-to-mesenchymal transition (EMT)-related transcription factor, encoded by Snai2, was highly expressed in MOC2-CD271 and HSC3-CD271, compared with respective parental cells. CD271 activation by NGF conferred enhanced invasiveness in CD271-overexpressing cells, which was abrogated by Snai2 knockdown. In PDXs and primary human HNSCC, CD271 expression correlated with higher Snai2 expression, greater nodal metastasis, and shorter disease-free survival. Conclusions: Activation of CD271 results in upregulation of Snai2/Slug, which, in turn, results in a more invasive phenotype and an enhanced capacity for metastasis to regional lymph nodes. These findings point to CD271 as a promising, therapeutic target for oral cancer metastasis. Clin Cancer Res; 24(3); 674–83. ©2017 AACR.
- 1 February 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 419-426
Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy
- 1 February 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 419-426
Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy
- Open Access
- 26 July 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (16) , 6854-6866
CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma
Tumor-initiating cells (TICs) in squamous cell carcinoma of the head and neck (SCCHN) are best characterized by their surface expression of CD44. Although there is great interest in identifying strategies to target this population, no marker of these cells has been found to be functionally active. Here, we examined the expression of the purported marker of normal human oral epithelial stem cells, CD271. We show that CD271 expression is restricted to a subset of the CD44+ cells. Using xenograft assays, we show that the CD44+CD271+ subpopulation contains the most tumorigenic cells. Loss of CD271 function results in a block in the G2-M phase of the cell cycle and a profound negative impact on the capacity of these cells to initiate tumor formation in vivo. Incubation with recombinant NGF results in enhanced phosphorylation of Erk, providing additional evidence that CD271 is functionally active. Finally, incubation of SCCHN cells with antibody to CD271 results in decreased Erk phosphorylation and decreased tumor formation in vivo. Thus, our data are the first to demonstrate that CD271 more specifically identifies the TIC subpopulation within the CD44+ compartment in SCCHN and that this receptor is a functionally active and targetable molecule.
- 26 July 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (16) , 6854-6866
Open AccessCD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma
Tumor-initiating cells (TICs) in squamous cell carcinoma of the head and neck (SCCHN) are best characterized by their surface expression of CD44. Although there is great interest in identifying strategies to target this population, no marker of these cells has been found to be functionally active. Here, we examined the expression of the purported marker of normal human oral epithelial stem cells, CD271. We show that CD271 expression is restricted to a subset of the CD44+ cells. Using xenograft assays, we show that the CD44+CD271+ subpopulation contains the most tumorigenic cells. Loss of CD271 function results in a block in the G2-M phase of the cell cycle and a profound negative impact on the capacity of these cells to initiate tumor formation in vivo. Incubation with recombinant NGF results in enhanced phosphorylation of Erk, providing additional evidence that CD271 is functionally active. Finally, incubation of SCCHN cells with antibody to CD271 results in decreased Erk phosphorylation and decreased tumor formation in vivo. Thus, our data are the first to demonstrate that CD271 more specifically identifies the TIC subpopulation within the CD44+ compartment in SCCHN and that this receptor is a functionally active and targetable molecule.
- 8 July 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (30) , 12391-12396
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
The aryl hydrocarbon receptor (AhR) has become increasingly recognized for its role in the differentiation and activity of immune cell subsets; however, its role in regulating the activity of natural killer (NK) cells has not been described. Here, we show that AhR expression is induced in murine NK cells upon cytokine stimulation. We show that in the absence of AhR, NK cells have reduced cytolytic activity and reduced capacity to control RMA-S tumor formation in vivo, despite having normal development and maturation markers. Although AhR was first identified to bind the xenobiotic compound dioxin, AhR is now known to bind a variety of natural exogenous (e.g., dietary) and endogenous ligands. We show that activation of AhR with an endogenous tryptophan derivative, 6-formylindolo[3,2- b ]carbazole, potentiates NK cell IFN-γ production and cytolytic activity. Further, administration of 6-formylindolo[3,2- b ]carbazole in vivo enhances NK cell control of tumors in an NK cell- and AhR-dependent manner. Finally, similar effects on NK cell potency occur with AhR dietary ligands, potentially explaining the numerous associations that have been observed in the past between diet and NK cell function. Our studies introduce AhR as another regulator of NK cell activity in vivo.
- 8 July 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (30) , 12391-12396
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
The aryl hydrocarbon receptor (AhR) has become increasingly recognized for its role in the differentiation and activity of immune cell subsets; however, its role in regulating the activity of natural killer (NK) cells has not been described. Here, we show that AhR expression is induced in murine NK cells upon cytokine stimulation. We show that in the absence of AhR, NK cells have reduced cytolytic activity and reduced capacity to control RMA-S tumor formation in vivo, despite having normal development and maturation markers. Although AhR was first identified to bind the xenobiotic compound dioxin, AhR is now known to bind a variety of natural exogenous (e.g., dietary) and endogenous ligands. We show that activation of AhR with an endogenous tryptophan derivative, 6-formylindolo[3,2- b ]carbazole, potentiates NK cell IFN-γ production and cytolytic activity. Further, administration of 6-formylindolo[3,2- b ]carbazole in vivo enhances NK cell control of tumors in an NK cell- and AhR-dependent manner. Finally, similar effects on NK cell potency occur with AhR dietary ligands, potentially explaining the numerous associations that have been observed in the past between diet and NK cell function. Our studies introduce AhR as another regulator of NK cell activity in vivo.
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (1_Suppleme) , B2
Abstract B2: T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Agonist anti-CD137(4-1BB) mAbs enhance CD8-mediated antitumor immunity. Agonist anti-human CD137 mAbs covering four distinct epitopes on the CD137 glycoprotein co-stimulated T cell activation irrespective of the engaged epitope or its interference with CD137L binding. CD137 perturbation with all these agonist mAbs resulted in antigen and antibody internalization towards a vesicular compartment. Internalization was observed in activated T cells from humans and mice, not only in culture but also in antibody-injected living animals. These in vivo experiments were carried out upon systemic intravenous injections with anti-CD137 mAbs and showed internalization in tumor-infiltrating lymphocytes and in activated human T cells transferred to mice. CD137-internalization required K63-polyubiquitination and endocytosed CD137-containing deposits were decorated with K63-polyubiquitins. CD137 stimulation activates NF-kB through a K63-linked polyubiquitination-dependent route and CD137-associated TRAF2 becomes K63-polyubiquitinated. Consistent with a role for TRAF2 in CD137 signalling, transgenic mice functionally deficient in TRAF2 show a delayed immunotherapeutic activity of anti-CD137 mAbs Citation Format: Ivan Martinez-Forero, Arantza Azpilicueta, Elixabet Bolaños-Mateo, Estnislao Nistal-Villan, Asis Palazon, Alvaro Teijeira, Gema Perez-Chacon, Aizea Morales-Kastresana, Oihana Murillo, Maria Jure-Kunkel, Juan Manuel Zapata, Ignacio Melero. T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B2.
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (1_Suppleme) , B2
Abstract B2: T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Agonist anti-CD137(4-1BB) mAbs enhance CD8-mediated antitumor immunity. Agonist anti-human CD137 mAbs covering four distinct epitopes on the CD137 glycoprotein co-stimulated T cell activation irrespective of the engaged epitope or its interference with CD137L binding. CD137 perturbation with all these agonist mAbs resulted in antigen and antibody internalization towards a vesicular compartment. Internalization was observed in activated T cells from humans and mice, not only in culture but also in antibody-injected living animals. These in vivo experiments were carried out upon systemic intravenous injections with anti-CD137 mAbs and showed internalization in tumor-infiltrating lymphocytes and in activated human T cells transferred to mice. CD137-internalization required K63-polyubiquitination and endocytosed CD137-containing deposits were decorated with K63-polyubiquitins. CD137 stimulation activates NF-kB through a K63-linked polyubiquitination-dependent route and CD137-associated TRAF2 becomes K63-polyubiquitinated. Consistent with a role for TRAF2 in CD137 signalling, transgenic mice functionally deficient in TRAF2 show a delayed immunotherapeutic activity of anti-CD137 mAbs Citation Format: Ivan Martinez-Forero, Arantza Azpilicueta, Elixabet Bolaños-Mateo, Estnislao Nistal-Villan, Asis Palazon, Alvaro Teijeira, Gema Perez-Chacon, Aizea Morales-Kastresana, Oihana Murillo, Maria Jure-Kunkel, Juan Manuel Zapata, Ignacio Melero. T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B2.
- Open Access
- 21 December 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e52370
Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy
Apolipoprotein A-I (Apo A-I) is a major component of high density lipoproteins (HDL) that transport cholesterol in circulation. We have constructed an expression plasmid encoding a chimeric molecule encompassing interleukin-15 (IL-15) and Apo A-I (pApo-hIL15) that was tested by hydrodynamic injections into mice and was co-administered with a plasmid encoding the sushi domain of IL-15Rα (pSushi) in order to enhance IL-15 trans-presentation and thereby bioactivity. The pharmacokinetics of the Apo A-I chimeric protein were much longer than non-stabilized IL-15 and its bioactivity was enhanced in combination with IL-15Rα Sushi. Importantly, the APO-IL-15 fusion protein was incorporated in part into circulating HDL. Liver gene transfer of these constructs increased NK and memory-phenotype CD8 lymphocyte numbers in peripheral blood, spleen and liver as a result of proliferation documented by CFSE dilution and BrdU incorporation. Moreover, the gene transfer procedure partly rescued the NK and memory T-cell deficiency observed in IL-15Rα−/− mice. pApo-hIL15+ pSushi gene transfer to the liver showed a modest therapeutic activity against subcutaneously transplanted MC38 colon carcinoma tumors, that was more evident when tumors were set up as liver metastases. The improved pharmacokinetic profile and the strong biological activity of APO-IL-15 fusion protein holds promise for further development in combination with other immunotherapies.
- 21 December 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e52370
Open AccessLiver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy
Apolipoprotein A-I (Apo A-I) is a major component of high density lipoproteins (HDL) that transport cholesterol in circulation. We have constructed an expression plasmid encoding a chimeric molecule encompassing interleukin-15 (IL-15) and Apo A-I (pApo-hIL15) that was tested by hydrodynamic injections into mice and was co-administered with a plasmid encoding the sushi domain of IL-15Rα (pSushi) in order to enhance IL-15 trans-presentation and thereby bioactivity. The pharmacokinetics of the Apo A-I chimeric protein were much longer than non-stabilized IL-15 and its bioactivity was enhanced in combination with IL-15Rα Sushi. Importantly, the APO-IL-15 fusion protein was incorporated in part into circulating HDL. Liver gene transfer of these constructs increased NK and memory-phenotype CD8 lymphocyte numbers in peripheral blood, spleen and liver as a result of proliferation documented by CFSE dilution and BrdU incorporation. Moreover, the gene transfer procedure partly rescued the NK and memory T-cell deficiency observed in IL-15Rα−/− mice. pApo-hIL15+ pSushi gene transfer to the liver showed a modest therapeutic activity against subcutaneously transplanted MC38 colon carcinoma tumors, that was more evident when tumors were set up as liver metastases. The improved pharmacokinetic profile and the strong biological activity of APO-IL-15 fusion protein holds promise for further development in combination with other immunotherapies.
- 7 August 2012
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 2 (6) , 465-470
CD44+ cells have cancer stem cell–like properties in nasopharyngeal carcinoma
Background: A subpopulation of cells within a tumor appears to have the exclusive ability to initiate tumors, self‐renew, and differentiate. These “cancer stem cells” (CSCs) are CD44+ in several epithelial malignancies. We examined the potential of CD44 to identify the CSC population in nasopharyngeal carcinoma (NPC).Methods: C666, an Epstein‐Barr virus–positive (EBV+) human NPC cell line, was stained for CD44 and sorted by fluorescence‐activated cell sorting (FACS). CD44+ and CD44− subpopulations were evaluated for (1) proliferative potential, (2) ability to differentiate, (3) expression of markers of epithelial‐to‐mesenchymal transition (EMT) and EBV genes, and (4) the ability to initiate tumors in vivo. Immunocompromised mice were injected with CD44+ and CD44− populations to assess the tumor‐initiating capacity. Immunohistochemistry for CD44 was performed on an 87‐patient tissue microarray (TMA), and clinical correlations were examined.Results: Heterogeneous expression of CD44 was seen among C666 cells. CD44+ cells differentiated into CD44− cells, indicating a hierarchical relationship. Further, CD44+ cells exhibited a more robust tumor‐initiating capacity in the xenograft model. However, no differences were seen in proliferation rates in vitro, EBV gene expression, or expression of EMT markers between CD44+ and CD44− subsets. Patient tumors were heterogeneous for CD44 staining, and a trend toward an association between CD44 expression and clinical outcome was observed.Conclusion: NPC contains a CD44+ subpopulation with features consistent with CSCs. There was a trend toward an association between CD44 expression within NPC tumors and decreased time to local failure/relapse in patients. © 2012 ARS–AAOA, LLC.
- 7 August 2012
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 2 (6) , 465-470
CD44+ cells have cancer stem cell–like properties in nasopharyngeal carcinoma
Background: A subpopulation of cells within a tumor appears to have the exclusive ability to initiate tumors, self‐renew, and differentiate. These “cancer stem cells” (CSCs) are CD44+ in several epithelial malignancies. We examined the potential of CD44 to identify the CSC population in nasopharyngeal carcinoma (NPC).Methods: C666, an Epstein‐Barr virus–positive (EBV+) human NPC cell line, was stained for CD44 and sorted by fluorescence‐activated cell sorting (FACS). CD44+ and CD44− subpopulations were evaluated for (1) proliferative potential, (2) ability to differentiate, (3) expression of markers of epithelial‐to‐mesenchymal transition (EMT) and EBV genes, and (4) the ability to initiate tumors in vivo. Immunocompromised mice were injected with CD44+ and CD44− populations to assess the tumor‐initiating capacity. Immunohistochemistry for CD44 was performed on an 87‐patient tissue microarray (TMA), and clinical correlations were examined.Results: Heterogeneous expression of CD44 was seen among C666 cells. CD44+ cells differentiated into CD44− cells, indicating a hierarchical relationship. Further, CD44+ cells exhibited a more robust tumor‐initiating capacity in the xenograft model. However, no differences were seen in proliferation rates in vitro, EBV gene expression, or expression of EMT markers between CD44+ and CD44− subsets. Patient tumors were heterogeneous for CD44 staining, and a trend toward an association between CD44 expression and clinical outcome was observed.Conclusion: NPC contains a CD44+ subpopulation with features consistent with CSCs. There was a trend toward an association between CD44 expression within NPC tumors and decreased time to local failure/relapse in patients. © 2012 ARS–AAOA, LLC.